KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income: 2016-2024

Historic Net Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$73.9 million.

  • Amneal Pharmaceuticals' Net Income rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 139.30%. This contributed to the annual value of -$73.9 million for FY2024, which is 51.55% down from last year.
  • As of FY2024, Amneal Pharmaceuticals' Net Income stood at -$73.9 million, which was down 51.55% from -$48.8 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Net Income registered a high of $68.6 million during FY2020, and its lowest value of -$254.8 million during FY2022.
  • For the 3-year period, Amneal Pharmaceuticals' Net Income averaged around -$125.8 million, with its median value being -$73.9 million (2024).
  • In the last 5 years, Amneal Pharmaceuticals' Net Income soared by 111.37% in 2020 and then slumped by 1,363.65% in 2022.
  • Amneal Pharmaceuticals' Net Income (Yearly) stood at $68.6 million in 2020, then slumped by 70.61% to $20.2 million in 2021, then crashed by 1,363.65% to -$254.8 million in 2022, then soared by 80.86% to -$48.8 million in 2023, then crashed by 51.55% to -$73.9 million in 2024.